Debbie Ali
Optometrist · North Miami, FLNPI 1669929204
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (38.7%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. Biotissue Holdings Inc. accounts for 86.7% of it on its own, with 23 other manufacturers making up the rest. Among optometrist clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 265 payments — averaging $219.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotissue Holdings Inc.$50K
- AbbVie$1K
- Bausch & Lomb Americas Inc.$1K
- NEW World Medical,inc.$698
- Sight Sciences, Inc.$518
- Oyster Point Pharma, Inc.$469
- plus $3K from 18 others
What the payments were for
- Consulting fees$22,50039%
- Speaking & faculty fees$10,30018%
- Travel & lodging$15,80927%
- Food & beverage$9,47416%
- Education$940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotissue Holdings Inc. | 88 | $50,457 |
| AbbVie(2 entities) | 45 | $1,466 |
| Bausch & Lomb Americas Inc. | 15 | $1,301 |
| NEW World Medical,inc. | 6 | $698 |
| Sight Sciences, Inc. | 15 | $518 |
| Oyster Point Pharma, Inc. | 11 | $469 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $388 |
| Sun Pharmaceutical Industries Inc. | 15 | $348 |
| Aerie Pharmaceuticals, Inc. | 6 | $317 |
| Novartis | 20 | $300 |
| Alcon | 9 | $286 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $268 |
| Optos, Inc. | 3 | $221 |
| Glaukos Corporation | 4 | $167 |
| Genentech USA, Inc. | 2 | $151 |
| Janssen Scientific Affairs, LLC | 1 | $150 |
| Tarsus Pharmaceuticals, Inc. | 5 | $136 |
| Maculogix, Inc. | 1 | $129 |
| Topcon Healthcare, Inc. | 1 | $122 |
| Eyevance Pharmaceuticals LLC | 2 | $96 |
| Kala Pharmaceuticals, Inc. | 3 | $79 |
| Dompe US, Inc. | 2 | $57 |
| Mallinckrodt Hospital Products Inc. | 1 | $33 |
| Johnson & Johnson | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prokera$14,961
- AmnioGraft$3,279
- MIEBO$919
- XIIDRA$794
- INFUSE$669
- Rocklatan$241
- Rhopressa$241
- Kahook Dual Blade$169
- Clearpath$169
- Ahmed Glaucoma Valve$169
- Streamline$169
- Balversa$150
- Erleada$150
- Abiraterone acetate$150
- LIPIFLOW SYSTEM ACTIVATOR (DISPOSABLE)$145
- OMNI(R) SURGICAL SYSTEM (US)$143
- Lucentis$137
- TYRVAYA$134
- AdaptDx$129
- ILUX$125
How this compares
$58,176 in reported general payments places this provider in the 95th percentile of 3,166 optometrist providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 333 | $242,501 |
| XiidraLifitegrast | 210 | $167,043 |
| LumiganBimatoprost | 208 | $124,489 |
| RhopressaNetarsudil Mesylate | 200 | $88,870 |
| XdemvyLotilaner | 41 | $76,508 |
| RocklatanNetarsudil Mesylat/Latanoprost | 151 | $76,186 |
| CombiganBrimonidine Tartrate/Timolol | 152 | $70,047 |
| MieboPerfluorohexyloctane/Pf | 38 | $32,776 |
| TyrvayaVarenicline Tartrate | 31 | $26,233 |
| Alphagan PBrimonidine Tartrate | 53 | $24,761 |
| VyzultaLatanoprostene Bunod | 37 | $16,626 |
| EysuvisLoteprednol Etabonate | 30 | $14,671 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 39 | $10,809 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 51 | $9,880 |
| CequaCyclosporine | 14 | $8,926 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $1,466 | $461,798746 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $1,301 | $216,445285 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $317 | $165,055351 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $136 | $76,50841 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $469 | $26,23331 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $79 | $14,67130 claims |
| AlconSimbrinza | $286 | $10,80939 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $348 | $8,92614 claims |
| Eyevance Pharmaceuticals LLCZerviate | $96 | $7,38923 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $388 | $1,23113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,166 optometrist providers in Florida.
Other optometrist in North Miami
- James HoffmanOrange Park$795K
- April JasperWest Palm Beach$553K
- Nora CothranLargo$505K
- Michael SluskyNorth Port$384K
- Katie SpearDefuniak Springs$361K
- Karen HoffmanOrange Park$282K
- Ashley RothMiami Beach$261K
- Jessica SteenDavie$256K
- Mark DunbarMiami$236K
- Robert DavisPembroke Pines$217K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.